Vancouver, British Columbia – ( March 24th, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article “A High-Performing Plasma Metabolite Panel for Early-Stage Lung Cancer Detection” has been published in the peer-reviewed journal Cancers, validating BioMark’s technology to detect early-stage (I/II) non-small cell lung cancer (NSCLC) using a simple blood plasma test. Rashid Bux, President and CEO, says, “This latest publication demonstrates our ability to further leverage our international team of leading clinicians, scientists, researchers and data scientists in discovery and validation studies for the development of early detection lung cancer diagnostic assay. The objective of the research was to use metabolomic techniques to discover and validate plasma metabolite biomarkers for the diagnosis of early-stage non-small cell lung cancer. The study included plasma samples from patients with biopsy-confirmed NSCLC along with age and gender-matched plasma samples from healthy controls. Robust predictive models were developed and validated using these metabolites and other, easily measured clinical data for detecting different stages of NSCLC. This study successfully identified and validated a simple, high-performing, metabolite-based test for detecting early stage (I/II) NSCLC patients in plasma.” The team consisted of Dr. David Wishart (Department of Biological Sciences, University of Alberta, Edmonton, AB), Lun Zhang (Department of Biological Sciences, University of Alberta, Edmonton, AB) Dr. Rupasri Mandal (Department of Biological Sciences, University of Alberta, Edmonton, AB) , Jiamin Zheng (Department of Biological Sciences, University of Alberta, Edmonton, AB) Jennifer Reid Department of Biological Sciences, University of Alberta, Edmonton, AB) Dr. Andrew Maksymiuk (CancerCare Manitoba),  Daniel Sitar (Department of Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba), Bram Ramjiawan (Asper Clinical Research Institute & Office of Clinical Research, St. Boniface Hospital, Winnipeg, Manitoba), Paramjit Tappia (Asper Clinical Research Institute & Office of Clinical Research, St. Boniface Hospital, Winnipeg, Manitoba), Dr. Christian Rolfo (Marlene and Stewart Greenebaum Comprehensive Cancer Centre, University of Maryland, School of Medicine Baltimore), and Alessandro Russo (Medical Oncology Unit A.O. Papardo & Department of Human Pathology, University of Messina). The recently published paper is available through: and Cancers 2020, 12(3), 622; “While very promising, further validation on larger and more diverse cohorts is still required. BioMark has commenced a Pan-Canadian collaboration with leading clinicians, scientists, biobank, leading research institutions, machine learning analysts, accredited lab, regulatory advisors and health technology assessment specialists to prime and develop the assay for early lung cancer detection and screening application which has significant global demand given the limitation of existing tests. The technology works, and we’ve been able to show that this is a superb experimental platform with major clinical potential,” says Rashid Bux. A key advantage of developing a blood based metabolomic test is that it can be easily converted into a low-cost, high-throughput assay that can be run at almost any clinical laboratory equipped with a standard triple-quadrupole mass spectrometer very efficiently. We estimate that a modified assay that is specific to the metabolites identified here require as little as 10 μL of plasma. These promising results suggest that a minimally invasive, high performance, high-throughput, low cost lung cancer screening assay might be developed that could be used to select patients for further follow-up and confirmation using LDCT or other lung imaging modalities. About Cancers Cancers (ISSN 2072-6694) is an international, peer-reviewed open access journal on oncology. It publishes article types including Research Papers, Reviews, Editorials, Communications, etc. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. The full experimental details must be provided so that the results can be reproduced. Scope of Journal We publish high-quality articles including basic, translational, and clinical studies on all tumor types ( Press Release – BIOMARK’S LIQUID BIOPSY ASSAY LEVEARING METABOLOMICS DEMONSTRATES UTILITY IN EARLY LUNG CANCER DETECTION    
Share this post:

Sign up for the latest Biomark news

No paperwork, no hassle. We keep things digital, easy and regular.

*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.

BioMark Diagnostics Inc.
FSE: 20B

Related articles ...

© 2024 BioMark Diagnostics Inc. All Rights Reserved. BioMark’s mission is to provide universal access to a new paradigm in cancer diagnostics using metabolomics.